GlassScriptPhysician profile
Amy Heidelberg
NPI 1982165080
$6,968.28
in general payments reported to CMS, 2019-2025
28 companies · $1,772 in 2025
The $1,772 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,125 · 2022: $1,532 · 2023: $1,209 · 2024: $1,330 · 2025: $1,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.37 |
| Education | $231.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,267.17 | 2021-2025 | |
| Ucb, INC. | $731.36 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $629.27 | 2021-2025 | |
| Incyte Corporation | $564.02 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $417.25 | 2023-2025 | Sotyktu, Abecma |
| Mayne Pharma Commercial LLC | $389.17 | 2021-2025 | |
| Pfizer INC. | $321.26 | 2021-2023 | |
| Almirall LLC | $315.42 | 2021-2024 | Klisyri |
| Genzyme Corporation | $308.04 | 2021-2025 | |
| Janssen Biotech, INC. | $277.15 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $257.64 | 2021-2023 | Adbry |
| Regeneron Healthcare Solutions, INC. | $222.31 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $215.49 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $214.55 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $206.68 | 2021-2024 | Cabtreo, Jublia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $197.65 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.06 | 2024-2025 | Spevigo |
| Dermavant Sciences, INC. | $74.77 | 2023-2024 | Vtama |
| Botanix Sb INC | $69.85 | 2025 | Sofdra |
| Journey Medical Corporation | $55.55 | 2022-2025 | |
| Vyne Pharmaceuticals INC. | $25.03 | 2021 | |
| Convatec INC. | $20.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $19.80 | 2021 | |
| Mission Pharmacal Company | $19.33 | 2022 | |
| Epi Health, LLC | $16.73 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.60 | 2024 | Apexicon E |
| Organon LLC | $12.98 | 2025 | Vtama |
| Amgen INC. | $11.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Heidelberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.